FY2025 EPS Estimates for Exelixis Lifted by William Blair

Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at William Blair upped their FY2025 earnings per share estimates for shares of Exelixis in a research report issued to clients and investors on Sunday, January 12th. William Blair analyst A. Hsieh now anticipates that the biotechnology company will post earnings per share of $1.69 for the year, up from their previous estimate of $1.44. The consensus estimate for Exelixis’ current full-year earnings is $1.69 per share.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million during the quarter, compared to analyst estimates of $490.31 million. During the same period in the previous year, the company earned $0.10 EPS. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year.

Several other research analysts have also weighed in on EXEL. UBS Group began coverage on Exelixis in a report on Thursday, September 19th. They set a “neutral” rating and a $30.00 target price on the stock. Morgan Stanley lifted their price objective on Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, October 11th. BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. Stifel Nicolaus lifted their price target on shares of Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, October 16th. Finally, Truist Financial increased their price objective on shares of Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $33.75.

Exelixis Stock Up 1.0 %

Shares of NASDAQ EXEL opened at $35.65 on Wednesday. Exelixis has a twelve month low of $20.01 and a twelve month high of $36.97. The stock has a market cap of $10.18 billion, a price-to-earnings ratio of 22.85, a P/E/G ratio of 0.88 and a beta of 0.53. The company’s fifty day moving average is $34.90 and its 200-day moving average is $28.99.

Insider Activity at Exelixis

In other news, EVP Dana Aftab sold 1,162 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the sale, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at $15,666,873. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 314,736 shares of company stock valued at $10,849,110. 2.85% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Exelixis

Several hedge funds have recently added to or reduced their stakes in EXEL. Los Angeles Capital Management LLC raised its position in shares of Exelixis by 124.0% in the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after purchasing an additional 991,494 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new position in Exelixis in the 3rd quarter valued at about $14,979,000. Farallon Capital Management LLC lifted its position in Exelixis by 1.6% during the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after acquiring an additional 424,000 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Exelixis by 12.7% during the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock worth $73,425,000 after acquiring an additional 370,199 shares during the period. Finally, Burney Co. acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $12,267,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.